年間契約型情報サービス

CNS Drug News

発行 Espicom Business Intelligence 商品コード 4626
出版日 年22回 年間契約型情報サービス ページ情報 英文 24 Pages
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
CNS Drug News CNS Drug News
出版日: 年22回 年間契約型情報サービス ページ情報: 英文 24 Pages
概要

今後の高年齢化社会に伴い、高年齢層特有の病気であるアルツハイマー病、パーキンソン病、脳卒中等とその治療薬研究の中心となるCNS(中枢神経系)とCNSドラッグに業界の関心が寄せられており、その傾向は、今後25年間でさらに増加すると考えられています。

医療機器、医薬品などに関する情報提供で世界的に高い評価を得ております英国の調査会社Espicom Business Intelligenceが発行するニューズレター"CNS Drug News"は、CNSドラッグとその製薬会社、各国のCNSドラッグ市場について豊富で多面的な情報を掲載して毎月お届け致します。

毎月掲載項目

  • 総合新情報
  • 会議一覧

毎月次の中からセレクトされ掲載される項目

  • 神経変性異常
  • 精神安定剤
  • 抗うつ剤
  • 精神異常
  • 鎮痛剤
  • 薬物依存症治療
  • 抗てんかん薬
  • 吐き気・めまい治療薬
  • 食生活異常
  • 脳血管異常
  • 国際会議のR&Dハイライト

目次
Product Code: 1462-656X

BMI View: Biogen Idec is seeking to diversify beyond multiple sclerosis and looking to fuel its future neurology drug pipeline, which if successful, would help the company to sustain growth. This acquisition will give the company the basis for a pipeline in an area of significant unmet need, expanding it beyond a single mid-stage candidate. The company will continue to look to expand its pipeline through acquisitions and partnerships.

Table of Contents

1 Expanded Portfolio Will Help Biogen Idec Sustain Growth

Neurodegenerative Disorders

3 Parkinson's Disease - Agreements

3 Neuropore/UCB Enter Worldwide Collaboration And Agreement

4 Genomic Data Partnerships Will Bolster Drug Development

5 Product Updates

5 FDA Approves AbbVie's Duopa For Motor Fluctuations In Advanced PD Patients

5 FDA Approves Rytary For PD

6 R&D

6 Phase II/III And III Trials Of Rasagiline For PD Start In Japan

6 Newron Initiates Phase II Study Of sNN0031 In PD

6 Alzheimer's Disease - Agreements

6 Investment In Alzheimer's R&D To Continue With Focus On Mild Disease

8 Adamas Receives USD30mn Milestone Payment From Actavis

8 Other Neurodegenerative Disorders - Agreements

8 Treeway/uniQure Collaborate To Develop Gene Therapy For ALS

8 Isis Earns Milestone For Advancing ISIS-SMNRx In Children With SMA

8 R&D

8 DSMB Recommends Continuation Of Masitinib Phase III Study In ALS

9 Newron Initiates Phase II Study Of sNN0029 In ALS

Anxiolytics/Sleep Disorders

9 Product Updates

9 Mundipharma Receives Positive EC Decision On Targin For RLS

Psychotic Disorders

10 Product Updates

10 Resubmitted Cariprazine Can Expect Slow Sales Growth

11 Neos Submits NDA For Methylphenidate XR-ODT For ADHD

11 New Fanapt Patent Listed In FDA's Orange Book

11 Sunovion Files Lurasidone Patent Infringement Lawsuits

11 R&D

11 Alkermes Reports Positive Results From ALKS 3831 Phase II Trial In Schizophrenia

12 Newron Reports NW-3509 Phase I Results; Phase II Study In Schizophrenia Planned

Analgesics/Anaesthetics

13 Agreements

13 Acura Partners With Egalet To Commercialise Oxaydo

13 Product Updates

13 Actavis Challenges US Abstral Patents

14 FDA Accepts With Priority Review Pernix' Treximet sNDA For Use In Adolescents

14 R&D

14 First Of Three Sativex Phase III Cancer Pain Trials Misses Primary Endpoint

15 Trevena Initiates Second Phase IIb Study Of TRV130 For Acute Postoperative Pain

Anti-Epileptics

15 Product Updates

15 FDA Accepts Aptiom sNDA For Review

16 R&D

16 Perampanel Phase III Trial Conducted In Asia Meets Primary Endpoint

Drugs used in Nausea & Vertigo

16 Product Updates

16 Helsinn Reaches Palonosetron Settlement With Sandoz

General Development News

17 R&D

17 FDA Grants ODD To Auspex' SD-809 For Tourette's Syndrome In Paediatric Population

Corporate Activity

17 Nucynta Deal Will More Than Double Depomed's Annual Net Product Sales

18 Roche To Acquire Trophos

19 Otsuka Completes Avanir Acquisition

19 CoLucid Raises Funds For Oral Lasmiditan Phase III Programme In Migraine

19 Amorfix To Centralise Operations In South San Francisco/Focus On Neurodegenerative Disease

19 NeuroPhage Raises Funds To Advance NPT088 Into The Clinic

Conference Listings

Back to Top